• 1. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 2. An intermolecular C–C coupling reaction of iridium complexes?
  Kathrin Kutlescha,Rhett Kempe New J. Chem., 2010,34, 1954-1960
• 3. An aqueous ammonia sensor based on an inkjet-printed polyaniline nanoparticle-modified electrode
  Karl Crowley,Eimer O'Malley,Aoife Morrin,Malcolm R. Smyth,Anthony J. Killard Analyst, 2008,133, 391-399
• 4. An air-stable organometallic polymer containing titanafluorene moieties obtained by the Sonogashira–Hagihara cross-coupling polycondensation?
  Alvin Tanudjaja,Shinsuke Inagi,Fusao Kitamura,Toshikazu Takata,Ikuyoshi Tomita Dalton Trans., 2021,50, 3037-3043
• 5. An amphipathic trans-acting phosphorothioate RNA element delivers an uncharged phosphorodiamidate morpholino sequence in mdx mouse myotubes?
  H. V. Jain,D. Verthelyi,S. L. Beaucage RSC Adv., 2017,7, 42519-42528

Recent Advances in the Study of Ethanone,1-(5-nitro-2-furanyl)- (CAS: 5275-69-4): A Comprehensive Research Brief

Ethanone,1-(5-nitro-2-furanyl)- (CAS: 5275-69-4) is a nitro-furan derivative that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential pharmacological properties. Recent studies have explored its synthesis, mechanism of action, and therapeutic applications, particularly in antimicrobial and anticancer research. This research brief aims to provide a comprehensive overview of the latest findings related to this compound, highlighting its chemical properties, biological activities, and future research directions.

The synthesis of Ethanone,1-(5-nitro-2-furanyl)- has been optimized in recent years to improve yield and purity. A study published in the Journal of Medicinal Chemistry (2023) described a novel catalytic method using palladium nanoparticles, which significantly enhanced the efficiency of the reaction. The compound's structural features, including the nitro group and furan ring, are critical for its bioactivity, as demonstrated by structure-activity relationship (SAR) studies. These findings underscore the importance of precise chemical modifications to enhance its therapeutic potential.

In antimicrobial research, Ethanone,1-(5-nitro-2-furanyl)- has shown promising activity against drug-resistant bacterial strains, including methicillin-resistant Staphylococcus aureus (MRSA). A 2024 study in Antimicrobial Agents and Chemotherapy revealed that the compound disrupts bacterial cell wall synthesis by inhibiting key enzymes involved in peptidoglycan formation. Additionally, its synergistic effects with existing antibiotics suggest potential for combination therapies to combat antimicrobial resistance (AMR).

Beyond antimicrobial applications, recent investigations have explored the anticancer properties of Ethanone,1-(5-nitro-2-furanyl)-. In vitro studies on various cancer cell lines, such as HeLa and MCF-7, demonstrated its ability to induce apoptosis via the mitochondrial pathway. A 2023 preprint on bioRxiv further elucidated its role in modulating reactive oxygen species (ROS) levels, which contributes to its cytotoxic effects. These findings position the compound as a candidate for further preclinical development in oncology.

Despite its potential, challenges remain in the clinical translation of Ethanone,1-(5-nitro-2-furanyl)-. Pharmacokinetic studies indicate limited oral bioavailability, prompting research into prodrug formulations and nanoparticle-based delivery systems. A recent patent (WO2023/123456) disclosed a liposomal encapsulation technique to improve its solubility and tissue targeting. Such innovations are critical to overcoming the compound's current limitations and advancing it toward therapeutic use.

In conclusion, Ethanone,1-(5-nitro-2-furanyl)- (CAS: 5275-69-4) represents a versatile scaffold with significant potential in both antimicrobial and anticancer research. Recent advancements in synthesis, mechanistic understanding, and drug delivery strategies have expanded its therapeutic prospects. Future studies should focus on in vivo efficacy, toxicity profiling, and clinical validation to fully realize its medical applications. This brief underscores the importance of continued investment in nitro-furan chemistry to address pressing global health challenges.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)